Stockscreener 앱 받기
0.29
10.06%
-0.033
전일 마감가:
$0.323
열려 있는:
$0.3256
하루 거래량:
336.60K
Relative Volume:
0.10
시가총액:
$4.81M
수익:
-
순이익/손실:
$-13.24M
주가수익비율:
-0.0328
EPS:
-8.83
순현금흐름:
$-16.85M
1주 성능:
-2.06%
1개월 성능:
-35.97%
6개월 성능:
-74.06%
1년 성능:
-91.06%
1일 변동 폭
$0.29
$0.333
1주일 범위
$0.23
$0.347
52주 변동 폭
$0.23
$5.48
Virpax Pharmaceuticals Inc Stock (VRPX) Company Profile
명칭
Virpax Pharmaceuticals Inc
전화
610-727-4597
주소
1055 WESTLAKES DRIVE, SUITE 300, BERWYN
VRPX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VRPX
Virpax Pharmaceuticals Inc
|
0.29 | 4.81M | 0 | -13.24M | -16.85M | -8.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
439.83 | 113.70B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
682.10 | 75.52B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
662.88 | 39.78B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.84 | 35.34B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.68 | 29.05B | 3.30B | -501.07M | 1.03B | -2.1146 |
Virpax Pharmaceuticals Inc 주식(VRPX)의 최신 뉴스
Virpax Secures Critical $6M Funding: What This Means for Probudur's Future - StockTitan
Virpax Pharmaceuticals Prices of $6 Million Public Offering of Common Stock - citybiz
Virpax Pharmaceuticals sets public offering at $0.20 per share - Investing.com India
Virpax Secures Critical $6M Funding: Game-Changing Move for Probudur Development - StockTitan
Virpax Pharmaceuticals stock hits 52-week low at $0.29 - MSN
What's Going With Penny Stock Virpax Pharmaceuticals On Monday? - MSN
Virpax Pharmaceuticals enacts reverse stock split - Investing.com
Virpax Pharmaceuticals enacts reverse stock split By Investing.com - Investing.com South Africa
Virpax Pharmaceuticals granted Nasdaq listing extension - Investing.com
Virpax Pharmaceuticals Regains Nasdaq Compliance - MSN
Amendments to Independent Contractor Agreements at Virpax Pharmaceuticals Clarify Roles and Responsibilities - Defense World
Virpax Updates Executive Agreements for Legal Compliance - TipRanks
Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Short Interest Update - Defense World
Virpax Pharmaceuticals, Inc. Appoints Jaydriane Panis to the Board - Marketscreener.com
Virpax Pharmaceuticals names new board director - Investing.com
Virpax Pharmaceuticals names new board director By Investing.com - Investing.com UK
Pre-market Movers: EWTX, TNXP, LNSR, VRDN... - RTTNews
Virpax Pharmaceuticals announces board member resignation By Investing.com - Investing.com South Africa
Virpax Pharmaceuticals announces board member resignation - Investing.com
Virpax Pharmaceuticals Announces Board Member Resignation - TipRanks
Virpax Pharmaceuticals stock hits 52-week low at $0.36 By Investing.com - Investing.com Canada
Virpax Pharmaceuticals stock hits 52-week low at $0.36 - Investing.com
Virpax Pharmaceuticals Extends Collaboration with NIH Center for Pain Management Innovation - MSN
VRPX (Virpax Pharmaceuticals) Enterprise Value : $3.71 Mil (As of Dec. 01, 2024) - GuruFocus.com
Virpax Pharmaceuticals lowers quorum requirement By Investing.com - Investing.com South Africa
Virpax Pharmaceuticals lowers quorum requirement - Investing.com India
Virpax Pharmaceuticals : Amendments to Bylaws Form 8 K - Marketscreener.com
Virpax Pharmaceuticals Announces Positive Results in Study for Long-Lasting Pain Relief Formulation - MSN
Virpax Pharmaceuticals regains Nasdaq compliance By Investing.com - Investing.com Nigeria
Virpax Pharmaceuticals regains Nasdaq compliance - Investing.com India
Virpax Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Virpax Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements and Makes Key Appointments - Defense World
Virpax Pharmaceuticals Strengthens Leadership and Expands Collaborations - TipRanks
Maxim Group Downgrades Virpax Pharmaceuticals (VRPX) - MSN
Virpax Announces Positive Results for the Swine Model Dose Range Finding Study for Probudur - Marketscreener.com
Why Is Virpax Pharmaceuticals Stock Gaining On Friday? - Benzinga
Virpax Pharmaceuticals extends NIH pain management research By Investing.com - Investing.com Australia
Virpax Pharma Gets Government Cooperation Deal Extension - Marketscreener.com
Virpax Pharmaceuticals extends NIH pain management research - Investing.com India
Virpax Announces Agreement with the U.S. Department of Health and Human Services for the Developmental Extension for NES100 Towards IND for Acute and Chronic Non-Cancer Pain Alternative - The Bakersfield Californian
Virpax Extends NIH Partnership for Novel Non-Addictive Pain Treatment Technology | VRPX Stock News - StockTitan
VRPX (Virpax Pharmaceuticals) Debt-to-EBITDA : 0.00 (As of Sep. 2024) - GuruFocus.com
Virpax Pharmaceuticals Inc (VRPX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.45%
5.38%
자본화:
|
볼륨(24시간):